Guest Editor's Memo

Advances in Pulmonary Hypertension

关键词: Cardiology;    WHO Group 1- Pulmonary Arterial Hypertension;    WHO Group 4;    PH Medications;    Cardiac MRI;    Chronic thromboembolic pulmonary hypertension;    Oral therapy;    IV therapy;    Subcutaneous therapy;    Inhaled therapy;    Prostacyclin;    Endothelin Receptor Antagonists;    Anticoagulation;    RV Size;    RV Function;    thromboendarterectomy;    endothelial dysfunction;    tricuspid regurgitation;    von Willebr;    Factor;    pre-clinical research;    CME;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

This issue of Advances is about looking forward, but I'd like to start by looking backward for some perspective. About 10 years ago, a small company called Actelion launched the first effective oral therapy for pulmonary arterial hypertension, bosentan, while another startup, United Therapeutics, launched subcutaneous treprostinil. Rather suddenly, our patients had 2 options other than intravenous epoprostenol, and a broader number of cardiology and pulmonary physicians became interested in recognizing, evaluating, and treating patients with pulmonary hypertension. Since that time, an enormous investment from industry partners and governmental authorities around the world has resulted in significant rewards. In the US, there now are 3 different parenteral therapies, 2 inhaled therapies, and 4 oral therapies. We are making meaningful clinical use of plasma brain natriuretic peptide levels and more sophisticated measurements of right ventricular function to risk stratify our patients. We continue to explore the benefits of combination therapy, and we are documenting patient outcomes in large scale registries more completely than ever before. Our collective work as an investigative community and the dedication of our patients to better their own lives has changed this disease in radical, measurable ways. The amazing volunteers and employees of the Pulmonary Hypertension Association have been central to this success.

【 授权许可】

All Rights reserved